DARZALEX Worldwide Net Trade Sales Hit $3.964B In Q1, With US Contributing $2.208B Under Genmab's Exclusive License To J&J

Benzinga Newsdesk www.benzinga.com Neutral 93.9%

Neg 0% Neu 93.9% Pos 0%

Net sales of DARZALEX in the first quarter of 2026 totaled USD 3,964 million
Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)

Comments

No comments yet. Be the first!

DARZALEX Worldwide Net Trade Sales Hit $3.964B In Q1, With US Contributing $2.208B Under Genmab&#39;s Exclusive License To J&amp;J